Le Lézard
Classified in: Health
Subjects: CCA, FDA, FVT

Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update

DUBLIN, Aug. 3, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Vyxeostm (daunorubicin and cytarabine) liposome for injection, which was approved by the U.S. Food and Drug Administration on August 3, 2017 for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

The webcast will include an overview of AML from invited physician experts as well as a Vyxeos overview from the company's senior management.

Interested parties may access the webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the webcast to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

For further reference information on AML, including Vyxeos pricing considerations, please click here. For full prescribing information, please visit www.vyxeos.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeostm (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio (defibrotide) in countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc)


Logo - http://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg 

These press releases may also interest you

at 03:00
BEVERLY HILLS, Calif., March 24, 2018 /PRNewswire-PRWeb/ -- ProstaGenix, named World's Best Prostate Supplement in 2017, proves effective not only by the National Health Federation and Prostatepillreport.com, but by the raving customer reviews...

23 mar 2018
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 14, 2018 to file lead plaintiff applications in a securities class action lawsuit against Acadia...

23 mar 2018
WASHINGTON, March 23, 2018 /PRNewswire-PRWeb/ -- The Elizabeth Dole Foundation released the following statement today on the passage and signing of the omnibus spending bill: "Those of us who care deeply about military and veteran caregivers ? the...

23 mar 2018
Live Oak Village At Hammond Senior Living is now under new ownership and management and has been re-named Oak Park Village At Hammond Assisted Living and Memory Care after an extensive community renovation and upgrade to its offerings and amenities....

23 mar 2018
Arena Pharmaceuticals, Inc. today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m. EDT.  The...

23 mar 2018
The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will be announcing federal measures to increase access to opioid treatment. Government of Canada officials will also hold a media technical briefing (teleconference only) following...

News published on 3 august 2017 at 10:15 and distributed by: